Financhill
Buy
59

LLY Quote, Financials, Valuation and Earnings

Last price:
$873.54
Seasonality move :
3.46%
Day range:
$873.43 - $894.40
52-week range:
$711.40 - $972.53
Dividend yield:
0.62%
P/E ratio:
74.56x
P/S ratio:
17.52x
P/B ratio:
55.26x
Volume:
2.9M
Avg. volume:
3.9M
1-year change:
17.13%
Market cap:
$784.2B
Revenue:
$45B
EPS (TTM):
$11.71

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.7% $981.47
AMGN
Amgen
$8.9B $5.08 8.64% 257.4% $315.54
MRNA
Moderna
$941.1M -$2.73 5.1% -1.24% $56.51
REGN
Regeneron Pharmaceuticals
$3.7B $11.19 9.12% 53% $926.66
VKTX
Viking Therapeutics
-- -$0.27 -- -25.22% $99.29
VRTX
Vertex Pharmaceuticals
$2.8B $4.02 5.83% 2.33% $497.91
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LLY
Eli Lilly and
$873.12 $981.47 $784.2B 74.56x $1.50 0.62% 17.52x
AMGN
Amgen
$297.93 $315.54 $160B 39.46x $2.38 3.07% 4.81x
MRNA
Moderna
$33.73 $56.51 $13B -- $0.00 0% 4.07x
REGN
Regeneron Pharmaceuticals
$696.02 $926.66 $76.1B 18.18x $0.88 0.13% 5.64x
VKTX
Viking Therapeutics
$31.63 $99.29 $3.5B -- $0.00 0% --
VRTX
Vertex Pharmaceuticals
$480.33 $497.91 $123.3B 26.10x $0.00 0% 11.31x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LLY
Eli Lilly and
70.33% 1.194 5.05% 0.59x
AMGN
Amgen
91.09% 0.218 43.85% 0.84x
MRNA
Moderna
-- -0.029 -- 3.35x
REGN
Regeneron Pharmaceuticals
6.33% 1.252 2.54% 3.86x
VKTX
Viking Therapeutics
-- 5.815 -- --
VRTX
Vertex Pharmaceuticals
-- 1.257 -- 2.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LLY
Eli Lilly and
$11.1B $6.1B 25.09% 80.24% 38.89% $726.6M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
MRNA
Moderna
$227M -$1.2B -29.09% -29.09% -128.99% $303M
REGN
Regeneron Pharmaceuticals
$3.2B $1B 14.73% 15.78% 25.56% $995.8M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$22M
VRTX
Vertex Pharmaceuticals
$2.5B $1.1B -3.23% -3.23% 39.12% $492M

Eli Lilly and vs. Competitors

  • Which has Higher Returns LLY or AMGN?

    Amgen has a net margin of 32.59% compared to Eli Lilly and's net margin of 6.9%. Eli Lilly and's return on equity of 80.24% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About LLY or AMGN?

    Eli Lilly and has a consensus price target of $981.47, signalling upside risk potential of 12.41%. On the other hand Amgen has an analysts' consensus of $315.54 which suggests that it could grow by 5.91%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 6 0
    AMGN
    Amgen
    9 15 2
  • Is LLY or AMGN More Risky?

    Eli Lilly and has a beta of 0.416, which suggesting that the stock is 58.369% less volatile than S&P 500. In comparison Amgen has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.064%.

  • Which is a Better Dividend Stock LLY or AMGN?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.62%. Amgen offers a yield of 3.07% to investors and pays a quarterly dividend of $2.38 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios LLY or AMGN?

    Eli Lilly and quarterly revenues are $13.5B, which are larger than Amgen quarterly revenues of $9.1B. Eli Lilly and's net income of $4.4B is higher than Amgen's net income of $627M. Notably, Eli Lilly and's price-to-earnings ratio is 74.56x while Amgen's PE ratio is 39.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.52x versus 4.81x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    17.52x 74.56x $13.5B $4.4B
    AMGN
    Amgen
    4.81x 39.46x $9.1B $627M
  • Which has Higher Returns LLY or MRNA?

    Moderna has a net margin of 32.59% compared to Eli Lilly and's net margin of -115.94%. Eli Lilly and's return on equity of 80.24% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
    MRNA
    Moderna
    23.5% -$2.91 $10.9B
  • What do Analysts Say About LLY or MRNA?

    Eli Lilly and has a consensus price target of $981.47, signalling upside risk potential of 12.41%. On the other hand Moderna has an analysts' consensus of $56.51 which suggests that it could grow by 67.52%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 6 0
    MRNA
    Moderna
    5 16 1
  • Is LLY or MRNA More Risky?

    Eli Lilly and has a beta of 0.416, which suggesting that the stock is 58.369% less volatile than S&P 500. In comparison Moderna has a beta of 1.589, suggesting its more volatile than the S&P 500 by 58.912%.

  • Which is a Better Dividend Stock LLY or MRNA?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.62%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or MRNA?

    Eli Lilly and quarterly revenues are $13.5B, which are larger than Moderna quarterly revenues of $966M. Eli Lilly and's net income of $4.4B is higher than Moderna's net income of -$1.1B. Notably, Eli Lilly and's price-to-earnings ratio is 74.56x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.52x versus 4.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    17.52x 74.56x $13.5B $4.4B
    MRNA
    Moderna
    4.07x -- $966M -$1.1B
  • Which has Higher Returns LLY or REGN?

    Regeneron Pharmaceuticals has a net margin of 32.59% compared to Eli Lilly and's net margin of 24.22%. Eli Lilly and's return on equity of 80.24% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
    REGN
    Regeneron Pharmaceuticals
    85.08% $8.06 $31.3B
  • What do Analysts Say About LLY or REGN?

    Eli Lilly and has a consensus price target of $981.47, signalling upside risk potential of 12.41%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $926.66 which suggests that it could grow by 33.14%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 6 0
    REGN
    Regeneron Pharmaceuticals
    12 7 0
  • Is LLY or REGN More Risky?

    Eli Lilly and has a beta of 0.416, which suggesting that the stock is 58.369% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.082, suggesting its less volatile than the S&P 500 by 91.799%.

  • Which is a Better Dividend Stock LLY or REGN?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.62%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or REGN?

    Eli Lilly and quarterly revenues are $13.5B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Eli Lilly and's net income of $4.4B is higher than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Eli Lilly and's price-to-earnings ratio is 74.56x while Regeneron Pharmaceuticals's PE ratio is 18.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.52x versus 5.64x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    17.52x 74.56x $13.5B $4.4B
    REGN
    Regeneron Pharmaceuticals
    5.64x 18.18x $3.8B $917.7M
  • Which has Higher Returns LLY or VKTX?

    Viking Therapeutics has a net margin of 32.59% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 80.24% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About LLY or VKTX?

    Eli Lilly and has a consensus price target of $981.47, signalling upside risk potential of 12.41%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 213.92%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 6 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is LLY or VKTX More Risky?

    Eli Lilly and has a beta of 0.416, which suggesting that the stock is 58.369% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.034%.

  • Which is a Better Dividend Stock LLY or VKTX?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.62%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or VKTX?

    Eli Lilly and quarterly revenues are $13.5B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $4.4B is higher than Viking Therapeutics's net income of -$35.4M. Notably, Eli Lilly and's price-to-earnings ratio is 74.56x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.52x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    17.52x 74.56x $13.5B $4.4B
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M
  • Which has Higher Returns LLY or VRTX?

    Vertex Pharmaceuticals has a net margin of 32.59% compared to Eli Lilly and's net margin of 31.35%. Eli Lilly and's return on equity of 80.24% beat Vertex Pharmaceuticals's return on equity of -3.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
    VRTX
    Vertex Pharmaceuticals
    85.46% $3.50 $16.4B
  • What do Analysts Say About LLY or VRTX?

    Eli Lilly and has a consensus price target of $981.47, signalling upside risk potential of 12.41%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.91 which suggests that it could grow by 3.66%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LLY
    Eli Lilly and
    15 6 0
    VRTX
    Vertex Pharmaceuticals
    16 12 1
  • Is LLY or VRTX More Risky?

    Eli Lilly and has a beta of 0.416, which suggesting that the stock is 58.369% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.713%.

  • Which is a Better Dividend Stock LLY or VRTX?

    Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.62%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios LLY or VRTX?

    Eli Lilly and quarterly revenues are $13.5B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.9B. Eli Lilly and's net income of $4.4B is higher than Vertex Pharmaceuticals's net income of $913M. Notably, Eli Lilly and's price-to-earnings ratio is 74.56x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.52x versus 11.31x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LLY
    Eli Lilly and
    17.52x 74.56x $13.5B $4.4B
    VRTX
    Vertex Pharmaceuticals
    11.31x 26.10x $2.9B $913M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Is PFE the Best Dividend Play in Its Industry?
Is PFE the Best Dividend Play in Its Industry?

By their inherent nature, established pharma companies face a demand…

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
5
TRUP alert for Feb 21

Trupanion [TRUP] is down 7.18% over the past day.

Sell
12
TFII alert for Feb 21

TFI International [TFII] is down 6.67% over the past day.

Sell
22
FRPT alert for Feb 22

Freshpet [FRPT] is down 5.76% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock